Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRK

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.

Benzinga

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data

Merck Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference.

Benzinga

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Merck Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

Benzinga

Is Merck Stock Outperforming the Dow?

As Merck has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

On Tuesday, Merck Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

Benzinga

Is Wall Street Bullish or Bearish on Merck Stock?

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.

Barchart

Read news from The Economist, FT, and more,
with one subscription

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

Barchart

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Benzinga

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Benzinga

S&P Futures Gain With Focus on U.S. JOLTs Report and Corporate Earnings, FOMC Meeting on Tap

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors shift their focus from recent U.S. trade deals to economic data, a new round of corporate earnings reports, and the start of the Federal Reserve’s two-day policy meeting.

Barchart

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

Merck Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29.

Benzinga

What You Need To Know Ahead of Merck's Earnings Release

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Barchart

Is Merck Stock Underperforming the Nasdaq?

Despite Merck’s recent underperformance relative to the Nasdaq, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Are Wall Street Analysts Bullish on Merck Stock?

While Merck has trailed the broader market over the past year, analysts still see a reasonably promising path ahead for the pharma heavyweight.

Barchart

Do Wall Street Analysts Like Pfizer Stock?

Pfizer has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Streak Analysis Alert: Why Merck (MRK) Should Be on Your Radar This Week

Blue chips like MRK stock generally represent a 50/50 wager for any given week. However, certain conditions strongly tilt the odds toward one side of the spectrum.

Barchart

What to Expect From Merck & Co.'s Next Quarterly Earnings Report

Merck & Co. will release its first-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Merck Stock Just Reminded Us Why ‘Buy the Dip’ Is Not That Simple

This healthcare company is down more than 30% over the past 52 weeks but still may not be a good buy for value investors.

MarketBeat

Institutional Investors Bet $1B on These 4 Stocks—Should You?

Institutional investors snapped up at least $1 billion in shares of each of these four companies in Q4 of 2024 - should you buy as well?

MarketBeat

These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?

This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys.

Barchart

Is Merck Stock Underperforming the S&P 500?

Despite Merck’s recent underperformance relative to the S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

MarketBeat

MarketBeat Week in Review – 02/10 - 02/14

Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in

MarketBeat

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

Kiplinger

Stock Market Today: Earnings Speak Louder Than Tariffs

Recent market reaction to Trump administration policy announcements has been "entirely normal."

1 2 3 4 5

People

Gabriel OsorioMazilli

50 stories

Jea Yu

23 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.